WebPHESGO is an FDA-approved treatment for HER2+ breast cancer. Whether your breast cancer is early or metastatic, PHESGO could be the treatment option that’s right for you. Get the conversation started with your doctor. PHESGO combines 2 HER2+ breast cancer treatments into 1 injection PERJETA and Herceptin are two HER2-targeted therapies. WebDec 18, 2024 · 1. Early Breast Cancer . Phesgo is indicated for use in combination with chemotherapy for: • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
PHESGO® (pertuzumab / trastuzumab / hyaluronidase-zzfx) A Treatm…
WebJun 29, 2024 · Phesgo is initially used in combination with chemotherapy and could … WebJun 29, 2024 · The recommended initial dose of PHESGO is 1,200 mg pertuzumab, 600 mg trastuzumab, and 30,000 units hyaluronidase administered subcutaneously over approximately 8 minutes, followed every 3 weeks... rockwood springs apartments
BLA 761170 BLA APPROVAL - Food and Drug Administration
WebJun 29, 2024 · The FDA has granted approval to phesgo – a combination of pertuzumab … WebMar 1, 2024 · • PHESGO recognizes the cancer cells in the body called “human epidermal growth factor 2” or HER2 for short. HER2 is found in large amounts on the surface of some cancer cells where it stimulates their growth. When PHESGO attaches to the HER2 cancer cells, it may slow or stop the cancer cells from growing, or may kill them. WebNov 16, 2024 · Neoadjuvant Treatment of Breast Cancer. Administer PHESGO every 3 weeks for 3 to 6 cycles as part of a treatment regimen for early breast cancer [see Clinical Studies (14.2)].. Refer to the prescribing information for pertuzumab, administered in combination with trastuzumab and chemotherapy, for recommended dose and dosage modifications. otters swimming team